Back to Search
Start Over
Inhibition of PLA2G4A attenuated valproic acid- induced lysosomal membrane permeabilization and restored impaired autophagic flux: Implications for hepatotoxicity.
- Source :
-
Biochemical pharmacology [Biochem Pharmacol] 2024 Sep; Vol. 227, pp. 116438. Date of Electronic Publication: 2024 Jul 25. - Publication Year :
- 2024
-
Abstract
- Valproic acid (VPA) has broad efficacy against several seizures but causes liver injury limiting its prolonged clinical use. Some studies have demonstrated that VPA-induced hepatotoxicity is characterized by microvesicular hepatic steatosis. However, novel detailed mechanisms to explain VPA-induced hepatic steatosis and experimentally rigorously validated protective agents are still lacking. In this study, 8-week-old C57BL/6J mice were gavaged with VPA (500 mg/kg/d) for 4 weeks to establish an in vivo model of VPA-induced chronic liver injury. Quantitative proteomic and non-targeted lipidomic analyses were performed to explore the underlying mechanisms of VPA-induced hepatotoxicity. As a result, VPA-induced hepatotoxicity is associated with impaired autophagic flux, which is attributed to lysosomal dysfunction. Further studies revealed that VPA-induced lysosomal membrane permeabilization (LMP), allows soluble lysosomal enzymes to leak into the cytosol, which subsequently led to impaired lysosomal acidification. A lower abundance of glycerophospholipids and an increased abundance of lysophospholipids in liver tissues of mice in the VPA group strongly indicated that VPA-induced LMP may be mediated by the activation of phospholipase PLA2G4A. Metformin (Met) acted as a potential protective agent attenuating VPA-induced liver dysfunction and excessive lipid accumulation. Molecular docking and cellular thermal shift assays demonstrated that Met inhibited the activity of PLA2G4A by directly binding to it, thereby ameliorating VPA-induced LMP and autophagic flux impairment. In conclusion, this study highlights the therapeutic potential of targeting PLA2G4A-mediated lysosomal dysfunction in VPA-induced hepatotoxicity.<br />Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2024. Published by Elsevier Inc.)
- Subjects :
- Animals
Mice
Male
Chemical and Drug Induced Liver Injury metabolism
Chemical and Drug Induced Liver Injury prevention & control
Chemical and Drug Induced Liver Injury pathology
Humans
Molecular Docking Simulation
Anticonvulsants pharmacology
Anticonvulsants toxicity
Intracellular Membranes drug effects
Intracellular Membranes metabolism
Permeability drug effects
Metformin pharmacology
Valproic Acid toxicity
Autophagy drug effects
Mice, Inbred C57BL
Lysosomes drug effects
Lysosomes metabolism
Group IV Phospholipases A2 metabolism
Group IV Phospholipases A2 antagonists & inhibitors
Subjects
Details
- Language :
- English
- ISSN :
- 1873-2968
- Volume :
- 227
- Database :
- MEDLINE
- Journal :
- Biochemical pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 39025409
- Full Text :
- https://doi.org/10.1016/j.bcp.2024.116438